Section Arrow
CAPR.NASDAQ
- Capricor Therapeutics
Quotes are at least 15-min delayed:2025/06/01 08:10 EDT
Last
 9.89
-0.2 (-1.98%)
Day High 
10.33 
Prev. Close
10.09 
1-M High
13.22 
Volume 
2.13M 
Bid
9.93
Ask
10.02
Day Low
9.58 
Open
9.92 
1-M Low
6.27 
Market Cap 
461.19M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 10.38 
20-SMA 9.42 
50-SMA 10.54 
52-W High 23.4 
52-W Low 3.52 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.37/-0.25
Enterprise Value
461.81M
Balance Sheet
Book Value Per Share
2.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
22.27M
Operating Revenue Per Share
0.21
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/06/01 08:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.